Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
$4.59
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.59
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$3.42 - $5.88
Previous CloseN/A
Volume4.84K
Average Volume (3M)122.41K
Market Cap
$215.43M
Enterprise Value$186.47M
Total Cash (Recent Filing)$26.49M
Total Debt (Recent Filing)$33.66M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 18, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding49,867,280
10 Day Avg. Volume115,275
30 Day Avg. Volume122,406
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-5.13
Price to Sales (P/S)4.51
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue5.18
Enterprise Value/Gross Profit6.12
Enterprise Value/Ebitda-7.28
Forecast
1Y Price Target
$11.60Price Target Upside152.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Product InnovationNew products like TriNav Large, TriGuide, and TriNav Flex are expected to drive market adoption and benefit the company in the long term.
Profitability OutlookThe company is expected to become adjusted-EBITDA positive, which indicates a move towards profitability.
Revenue GrowthThe company reiterated guidance for revenue growth in 2025 of 50%+, which is expected to be driven by continued commercial efforts in liver-directed therapies.
Bears Say
Financial PerformanceGross margin of 83.9% missed our 86% estimate, and adjusted EBITDA of ($5.3M) also missed our ($4.3M) estimate.
Short-term Financial ChallengesThere is an expectation of a slower ramp in profitability as the company reinvests, indicating short-term financial challenges.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.42 and its highest was $5.88 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $215.43M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 18, 2025 which is in 34 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 12, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.207 by -$0.063.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 49,867,280 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.207. Following the earnings report the stock price went up 8.219%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
TriSalus Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.60 (152.72% Upside)
$11.60 (152.72% Upside)
Blogger Sentiment
Neutral
TLSI Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 265.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.5%
Last 30 Days ▼ 11.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.25%
12-Months-Change
Fundamentals
Return on Equity
271.41%
Trailing 12-Months
Asset Growth
27.40%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant revenue growth, successful product launches, and strategic capital raises. However, there were challenges with gross margin decline, increased administrative expenses, and a delay in achieving EBITDA positivity. Overall, the positive aspects of growth and expansion outweigh the financial setbacks.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$11.60
▲(152.72% Upside)
Technical Analysis
Ownership Overview
29.98% Insiders
2.00% Mutual Funds
11.51% Other Institutional Investors
54.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---